How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

4,365 results for

adhd Cognitive behavioural therapy

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

4341. A Dose-Ranging Study of the Efficacy of ABT-894 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Last Update Posted : November 2, 2010 Sponsor: Abbott Information provided by: Abbott Study Details Study Description Go to Brief Summary: A Dose-Ranging Study of the Efficacy of ABT-894 in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD) Condition or disease Intervention/treatment Phase Attention-Deficit/Hyperactivity Disorder ADHD Drug: ABT-894 Drug: atomoxetine Drug: placebo Phase 2 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial (...) : M06-818 First Posted: January 31, 2007 Last Update Posted: November 2, 2010 Last Verified: September 2010 Additional relevant MeSH terms: Layout table for MeSH terms Disease Attention Deficit Disorder with Hyperactivity Hyperkinesis Pathologic Processes Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Dyskinesias Neurologic Manifestations Nervous System Diseases Signs and Symptoms Atomoxetine Hydrochloride Adrenergic Uptake Inhibitors

2007 Clinical Trials

4342. Study of Aripiprazole (Abilify) in Children With ADHD (Attention Deficit Hyperactivity Disorder)

22, 2005 Last Update Posted: December 15, 2014 Last Verified: June 2013 Keywords provided by Robert L Findling, MD, University Hospitals Cleveland Medical Center: ADHD Additional relevant MeSH terms: Layout table for MeSH terms Attention Deficit Disorder with Hyperactivity Hyperkinesis Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Dyskinesias Neurologic Manifestations Nervous System Diseases Signs and Symptoms Aripiprazole Antidepressive Agents (...) : University Hospitals Cleveland Medical Center Collaborator: Bristol-Myers Squibb Information provided by (Responsible Party): Robert L Findling, MD, University Hospitals Cleveland Medical Center Study Details Study Description Go to Brief Summary: To look at the cognitive effects of abilify in children with a primary diagnosis of Attention Deficit Hyperactivity Disorder. To examine the safety, effectiveness and tolerability of abilify in children with a primary diagnosis of Attention Deficit

2005 Clinical Trials

4343. 1Controlled evaluation of a neurofeedback training of slow cortical potentials in children with Attention Deficit/Hyperactivity Disorder (ADHD) Full Text available with Trip Pro

1Controlled evaluation of a neurofeedback training of slow cortical potentials in children with Attention Deficit/Hyperactivity Disorder (ADHD) Although several promising studies on neurofeedback training in Attention Deficit/Hyperactivity Disorder (ADHD) have been performed in recent years, the specificity of positive treatment effects continues to be challenged.To evaluate the specificity of a neurofeedback training of slow cortical potentials, a twofold strategy was pursued: First (...) training group improved more than children who had participated in a group therapy program, particularly in attention and cognition related domains. On neuropsychological measures children of both groups showed similar improvements. However, only about half of the neurofeedback group learned to regulate cortical activation during a transfer condition without direct feedback. Behavioural improvements of this subgroup were moderately related to neurofeedback training performance, whereas effective

2007 Behavioral and brain functions : BBF

4344. An investigation of visuospatial memory impairment in children with attention deficit hyperactivity disorder (ADHD), combined type. (Abstract)

An investigation of visuospatial memory impairment in children with attention deficit hyperactivity disorder (ADHD), combined type. Memory impairment is not considered a core cognitive feature of attention deficit hyperactivity disorder, combined type (ADHD-CT), although it is associated with impairments in attentional and executive functions. This study investigates visuospatial memory impairment, in particular encoding and retrieval aspects, in children with ADHD-CT who are stimulant (...) dysfunction of the encoding rather than retrieval phase of visuospatial memory.Careful study of large ADHD-CT samples does detect deficits in a visuospatial memory task, but these reflect attentional deficits rather than being specifically due to dysfunction of the medial temporal lobe explicit memory system. Children with ADHD-CT may benefit from cognitive and behavioural strategies focused on improving encoding of relevant information rather than retrieval strategies.

2005 Psychological Medicine

4345. Single Versus Combination Medication Treatment for Children With Attention Deficit Hyperactivity Disorder

) First Posted: January 31, 2007 Results First Posted: June 14, 2017 Last Update Posted: June 14, 2017 Last Verified: May 2017 Keywords provided by James McCracken, University of California, Los Angeles: ADHD Guanfacine Methylphenidate Focalin XR Pediatric Cognitive function Combination therapy Additional relevant MeSH terms: Layout table for MeSH terms Attention Deficit Disorder with Hyperactivity Hyperkinesis Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental (...) Intervention/treatment Phase Attention Deficit Disorder With Hyperactivity Drug: Guanfacine Drug: Methylphenidate (MPH) Phase 4 Detailed Description: Attention deficit hyperactivity disorder (ADHD) is one of the most common childhood mental disorders. Children with ADHD have impaired functioning in multiple settings, including home and school. They also have difficulty relating with peers. If left untreated, the disorder may cause adverse effects that can last into adolescence and adulthood. Stimulant

2007 Clinical Trials

4346. Effect of extended release stimulant-based medications on neuropsychological functioning among adolescents with Attention-Deficit/Hyperactivity Disorder. Full Text available with Trip Pro

Effect of extended release stimulant-based medications on neuropsychological functioning among adolescents with Attention-Deficit/Hyperactivity Disorder. Attention-Deficit/Hyperactivity Disorder (ADHD) is associated with diminished neuropsychological functioning. This randomized, double-blind, placebo controlled, study is the first comparison of two extended release stimulant-based medications (Adderall XR and Concerta) and placebo on ADHD neuropsychological functioning. Adolescents diagnosed (...) with ADHD (n=35, 19 males) completed three separate assessments (5, 8, 11 p.m.) on three different days and medications (Concerta, Adderall XR and Placebo). The assessments consisted of two different neuropsychological tests, the Delayed Matching-to-Sample and the Go/No-go (GNG), which measure visual memory, attention span, and response inhibition. Results indicated a significant effect of medication on signs of impulsivity and memory. Simple contrasts showed significant improvement

2006 Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists Controlled trial quality: uncertain

4347. Attention Deficit Hyperactivity Disorder (ADHD) in Adolescents With Substance Use Disorders (SUD)

Phase ADHD Substance Abuse Drug: Methylphenidate (OROS-MPH) Drug: Methylphenidate (OROS-MPH) - Placebo Phase 3 Detailed Description: Research shows a high prevalence of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents with substance abuse disorders and indicates that they have poorer substance use treatment outcomes and poorer prognosis and risk of persistence and progression of drug use and behavior problems into adulthood. Although research indicates that the majority are not treated (...) Controlled Trial of Osmotic-Release Methylphenidate (OROS-MPH) for Attention Deficit Hyperactivity Disorder (ADHD) in Adolescents With Substance Use Disorders (SUD) Study Start Date : February 2006 Actual Primary Completion Date : October 2008 Actual Study Completion Date : October 2008 Resource links provided by the National Library of Medicine related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Active Comparator: Methylphenidate Drug: Methylphenidate (OROS-MPH

2005 Clinical Trials

4348. Atomoxetine Versus Placebo for Symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents With Autism Spectrum Disorder

table for MeSH terms Disease Attention Deficit Disorder with Hyperactivity Hyperkinesis Autism Spectrum Disorder Autistic Disorder Pathologic Processes Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Dyskinesias Neurologic Manifestations Nervous System Diseases Signs and Symptoms Child Development Disorders, Pervasive Atomoxetine Hydrochloride Adrenergic Uptake Inhibitors Neurotransmitter Uptake Inhibitors Membrane Transport Modulators Molecular (...) Atomoxetine Versus Placebo for Symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents With Autism Spectrum Disorder Atomoxetine Versus Placebo for Symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents With Autism Spectrum Disorder - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved

2006 Clinical Trials

4349. Attention Deficit Hyperactivity Disorder. (Abstract)

Attention Deficit Hyperactivity Disorder. Management of attention deficit hyperactivity disorder (ADHD) encompasses two general domains: pharmacologic therapies and nonpharmacologic therapies, including educational, cognitive-behavioral, and other psychological and psychiatric approaches. Within the past year there have been two seminal developments in treatment. The first is that the Evidence-based Practice Center at McMaster University, under contract with the Agency for Health Care Policy (...) and Research, produced an evidence based report on the treatment of ADHD. The topic was proposed to the AHCPR by the American Academy of Pediatrics and American Psychiatric Association, who served as partners to the center. The second is the completion of the Multisite Multimodal Treatment Study of Children with Attention-Deficit/Hyperactivity Disorder (MTA) study by the National Institutes of Mental Health, a 14-month double-blind placebo trial of medication and behavioral therapy in ADHD. In general

2001 Current Treatment Options in Neurology Controlled trial quality: uncertain

4350. Study of Attention Deficit/Hyperactivity Disorder Using Transcranial Magnetic Stimulation

Institutes of Health Clinical Center (CC): Cortical Stimulation Motor Control Neuromotor Maturation Magnetic Stimulation Attention Deficit Hyperactivity Disorder Hearing Loss Hearing Conservation Hearing Protective Devices Safety Study Noise Induced Hearing Loss Normal Volunteer Additional relevant MeSH terms: Layout table for MeSH terms Disease Attention Deficit Disorder with Hyperactivity Hyperkinesis Pathologic Processes Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders (...) and of children with corticospinal tract lesions, it has been postulated that these subtle motor signs reflect neurodevelopmental immaturity of the intracortical and interhemispheric inhibitory systems and that their disappearance occurs as a result of maturation. The presence of subtle neurological signs can accurately distinguish children with attention-deficit/hyperactivity disorder (ADHD) from healthy controls. The increased intensity of these neurological signs in younger age groups and their persistence

1999 Clinical Trials

4351. Iron treatment in children with attention deficit hyperactivity disorder. A preliminary report. (Abstract)

Iron treatment in children with attention deficit hyperactivity disorder. A preliminary report. Iron plays a role in the regulation of dopaminergic activity. In the present study, nonanemic children with attention deficit hyperactivity disorder (ADHD) were evaluated with regard to heme and nonheme iron metabolism and the effect of short-term iron administration on behavior. The study group consisted of 14 boys aged 7-11 years. All first underwent testing to rule out other psychiatric (...) and medical problems. The severity of the ADHD symptoms was determined by parent and teacher scores on the Connors Rating Scale. Thereafter, each patient received an iron preparation (Ferrocal), 5 mg/kg/day for 30 days. Blood samples were taken before and after drug administration. Results showed a significant increase in serum ferritin levels (from 25.9 +/- 9.2 to 44.6 +/- 18 ng/ml) and a significant decrease on the parents' Connors Rating Scale scores (from 17.6 +/- 4.5 to 12.7 +/- 5.4). There were

1997 Neuropsychobiology

4352. Multimodal Treatment Study of Children With Attention Deficit and Hyperactivity Disorder (MTA)

-term (10 months post-treatment) follow-up at 24 months. This continuation extends the follow-up to assessments at 36, 60, and 84 months after treatment. A child may be eligible for this study if he/she: Is 7 - 9 years old, and has Attention Deficit Hyperactivity Disorder (ADHD). Condition or disease Intervention/treatment Phase Attention Deficit Disorder With Hyperactivity Substance-related Disorders Dyssocial Behavior Behavioral: Psychosocial treatment Drug: Anti-ADHD medication Behavioral (...) Cognition Combined Modality Therapy Female Human Male Peer Group Risk Factors Treatment Outcome Attention Deficit Disorder with Hyperactivity -- *therapy Attention Deficit Disorder with Hyperactivity -- drug therapy Attention Deficit Disorder with Hyperactivity -- psychology Additional relevant MeSH terms: Layout table for MeSH terms Disease Attention Deficit Disorder with Hyperactivity Hyperkinesis Substance-Related Disorders Antisocial Personality Disorder Pathologic Processes Attention Deficit

1999 Clinical Trials

4353. An open trial of venlafaxine in the treatment of attention-deficit/hyperactivity disorder in children and adolescents. (Abstract)

An open trial of venlafaxine in the treatment of attention-deficit/hyperactivity disorder in children and adolescents. A 5-week open trial of venlafaxine was conducted in 16 children and adolescents (mean age 11.6 years) with attention-deficit/hyperactivity disorder (ADHD) in order to estimate the appropriate dosage range and to determine the extent of side effects. Subjects were evaluated using a structured clinical interview and a computerized diagnostic assessment, and subjects diagnosed (...) effects of venlafaxine on reaction times or on the number of commission and omission errors on CPT. Three ADHD subjects displayed a worsening of their hyperactivity and required discontinuation of venlafaxine, and nausea led to drug discontinuation in 1 patient. The mean daily dose of venlafaxine was 60 mg (1.4 mg/kg), administered 2-3 divided doses, there were no effects on blood pressure or heart rate. In this sample, low doses of venlafaxine appeared to be effective in reducing behavioral

1996 Journal of Child and Adolescent Psychopharmacology

4354. Comparing guanfacine and dextroamphetamine for the treatment of adult attention-deficit/hyperactivity disorder. (Abstract)

included the DSM-IV ADHD Behavior Checklist for Adults and the Copeland Symptom Checklist for Adult Attention Deficit Disorders. Cognitive measures of attention included the Stroop and Controlled Oral Word Association Test using the letters "C," "F," and "L" (COWAT, CFL version). For each trial, the drug was administered daily and titered up to optimal doses of maximum efficacy but with a minimum of side effects, and then data were collected. Both drugs significantly reduced ADHD symptoms on the DSM-IV (...) Comparing guanfacine and dextroamphetamine for the treatment of adult attention-deficit/hyperactivity disorder. The objective of this study was to compare the efficacy of the alpha-2a agonist guanfacine with that of dextroamphetamine for the treatment of adult attention-deficit/hyperactivity disorder (ADHD). Seventeen adult outpatients who met DSM-IV criteria for ADHD participated in a double-blind, placebo-controlled, crossover study comparing drug effects on ADHD symptoms. Measures of change

2001 Journal of Clinical Psychopharmacology Controlled trial quality: uncertain

4355. Immediate effects of methylphenidate on cognitive attention skills of children with attention-deficit-hyperactivity disorder. (Abstract)

Immediate effects of methylphenidate on cognitive attention skills of children with attention-deficit-hyperactivity disorder. This study investigated the immediate effects of stimulant medication (methylphenidate) on cognitive attention processes in children with attention-deficit-hyperactivity disorder (ADHD). Thirteen males and two females (mean age 9 y 5 mo, SD 18.3 mo) with a diagnosis of ADHD and who were to be prescribed methylphenidate were assessed twice on one day with the Test (...) of Everyday Attention for Children, a neuropsychological battery designed to tap different aspects of cognitive attention. Between assessments, the children were administered methylphenidate (10 mg). Each child had at least average intelligence (IQ 80 or over, as measured by the Wechsler Intelligence Scale for Children-III UK) and was on no other medication. A group of 16 children, who were matched for age, sex, and intelligence, also performed the cognitive tests twice on the same day to control

2005 Developmental Medicine and Child Neurology

4356. The alpha-2A adrenoceptor agonist guanfacine improves sustained attention and reduces overactivity and impulsiveness in an animal model of Attention-Deficit/Hyperactivity Disorder (ADHD) Full Text available with Trip Pro

The alpha-2A adrenoceptor agonist guanfacine improves sustained attention and reduces overactivity and impulsiveness in an animal model of Attention-Deficit/Hyperactivity Disorder (ADHD) ADHD is currently defined as a cognitive/behavioral developmental disorder where all clinical criteria are behavioral. Overactivity, impulsiveness, and inattentiveness are presently regarded as the main clinical symptoms. There is no biological marker, but there is considerable evidence to suggest that ADHD (...) behavior is associated with poor dopaminergic and noradrenergic modulation of neuronal circuits that involve the frontal lobes. The best validated animal model of ADHD, the Spontaneously Hypertensive Rat (SHR), shows pronounced overactivity, impulsiveness, and deficient sustained attention. While dopamine release is decreased in SHR prefrontal cortex, norepinephrine concentrations are elevated. The noradrenergic system appears to be hyperactive as a result of impaired alpha-2A adrenoceptor regulation

2006 Behavioral and Brain Functions

4357. Project Attention Deficit Hyperactivity Disorder (ADHD) and Electroencephalography (EEG)-Neurofeedback THERapy

8, 2013 Last Verified: March 2013 Keywords provided by Prof. Jan Buitelaar, Radboud University: ADHD Children EEG-Neurofeedback Additional relevant MeSH terms: Layout table for MeSH terms Attention Deficit Disorder with Hyperactivity Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders (...) Project Attention Deficit Hyperactivity Disorder (ADHD) and Electroencephalography (EEG)-Neurofeedback THERapy Project Attention Deficit Hyperactivity Disorder (ADHD) and Electroencephalography (EEG)-Neurofeedback THERapy - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved

2008 Clinical Trials

4358. Cognitive Behavioral Therapy for Treatment of Adult Attention Deficit Hyperactivity Disorder

Behavioral: Cognitive behavioral therapy (CBT) Other: Relaxation techniques and education about ADHD Not Applicable Detailed Description: Attention deficit hyperactivity disorder (ADHD), previously believed to be a disorder of childhood, affects as many as 5 percent of adults. Adults with ADHD are at high risk for academic and occupational underachievement, relationship difficulties, and reduced quality of life. This study will determine whether cognitive behavioral therapy (CBT) is more effective than (...) Cognitive Behavioral Therapy for Treatment of Adult Attention Deficit Hyperactivity Disorder Cognitive Behavioral Therapy for Treatment of Adult Attention Deficit Hyperactivity Disorder - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more

2005 Clinical Trials

4359. Group-Based Behavioral Therapy Combined With Stimulant Medication for Treating Children With Attention Deficit Hyperactivity Disorder and Impaired Mood

combined with stimulant medication in treating children with attention deficit hyperactivity disorder plus impairments in mood. Condition or disease Intervention/treatment Phase Attention Deficit Disorder With Hyperactivity Behavioral: Group-based behavior therapy Drug: Stimulant medication therapy Behavioral: Community-based psychosocial treatment Not Applicable Detailed Description: There has been increasing recognition that many children with attention deficit hyperactivity disorder (ADHD) exhibit (...) Group-Based Behavioral Therapy Combined With Stimulant Medication for Treating Children With Attention Deficit Hyperactivity Disorder and Impaired Mood Group-Based Behavioral Therapy Combined With Stimulant Medication for Treating Children With Attention Deficit Hyperactivity Disorder and Impaired Mood - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved

2008 Clinical Trials

4360. Treatment of Adult Attention Deficit Hyperactivity Disorder (ADHD) in Methadone Patients

Psychiatric Institute Collaborator: National Institute on Drug Abuse (NIDA) Information provided by (Responsible Party): Frances R Levin, New York State Psychiatric Institute Study Details Study Description Go to Brief Summary: The purpose of this study is to treat Adult Attention Deficit Hyperactivity Disorder (ADHD) in methadone patients. Condition or disease Intervention/treatment Phase ADHD Opioid-Related Disorders Cocaine Dependence Drug: Methylphenidate Drug: Bupropion Other: Placebo Phase 2 Phase 3 (...) -Related Disorders Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Substance-Related Disorders Chemically-Induced Disorders Methylphenidate Bupropion Methadone Central Nervous System Stimulants Physiological Effects of Drugs Dopamine Uptake Inhibitors Neurotransmitter Uptake Inhibitors Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Dopamine Agents Neurotransmitter Agents Antidepressive Agents, Second-Generation

2003 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>